Indian patients go to court over cancer drugBMJ 2004; 329 doi: https://doi.org/10.1136/bmj.329.7463.419 (Published 19 August 2004) Cite this as: BMJ 2004;329:419
- Ganapati Murdur
- New Delhi
India's Supreme Court has admitted a petition from an organisation representing cancer patients that challenges the government's decision to grant Novartis the exclusive marketing rights for imatinib, a drug that has emerged as a frontline treatment for chronic myeloid leukaemia.
The petitioner, the Cancer Patients Aid Association, has said that exclusive marketing rights for the drug would eliminate cheaper generic versions of the drug and make the treatment unaffordable to thousands of patients in India.
“Shutting down access to the drug by making it unaffordable is tantamount to denying patients the right to life,” said Mr Yogendra Sapru, …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial